healthy control
[대역어] None
[용어속성] Patient
[용어속성] Patient
Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study
Article
Published on
Journal: Human vaccines & immunotherapeutics
[Category] COVID19(2023년), SARS, 진단, 치료기술,
Journal: Human vaccines & immunotherapeutics
[Category] COVID19(2023년), SARS, 진단, 치료기술,
[키워드] acute respiratory syndrome
antibodies
antibody
Blood
C-reactive protein
carried
Cell
China
CLIA
Coronavirus-2
COVID-19
COVID-19 vaccination
COVID-19 vaccine
decrease
described
detect
distribution
dose
effective
Effectiveness
healthy control
high-risk population
ICV
IgG
immunization
immunoassay
immunogenicity
immunosuppressive agent
inactivated
Inactivated vaccine
Infection
inoculated
Logistic regression analysis
magnitude
methotrexate
parameter
Patient
patients
patients treated
positive response
Prednisolone
Prospective Study
Protective antibody
receiving
recruited
response to vaccination
rheumatic disease
Safe
Safety
Safety.
SARS-CoV-2
serious adverse reaction
South
[DOI] 10.1080/21645515.2022.2090176 PMC 바로가기
[DOI] 10.1080/21645515.2022.2090176 PMC 바로가기
Microvascular and proteomic signatures overlap in COVID-19 and bacterial sepsis: the MICROCODE study
Article
[키워드] 28-day mortality
adult COVID-19 patients
Analysis
Bacterial
Bacterial sepsis
Biomarker
clinical outcomes
Clinical severity
Cluster
Cohort
conditions
coronavirus disease
Correlation analysis
COVID-19
COVID-19 patient
dimension
disease
disease entity
dysfunction
endothelial
Endothelial dysfunction
explained
Health
healthy control
high mortality
Hospitalized
hospitals
host response
impairment
independent
intubation
marker
Microcirculation
Microscopy
Microvascular dysfunction
microvascular injury
outcome analysis
outcomes
overlap
patients
plasma
plasma protein
predict
predictor
Protein
proteome
proteomic
Proteomic signature
proteomics
quantified
sepsis.
Variation
was performed
was used
were measured
were used
[DOI] 10.1007/s10456-022-09843-8 PMC 바로가기
[DOI] 10.1007/s10456-022-09843-8 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study
Article
[키워드] adjusted
age
All participant
anti-SARS-CoV-2
anti-TNF
antibody
Antibody binding
antibody concentration
Antibody concentrations
approved
available data
boost
booster
case-control study
combination therapy
Concentration
control group
COVID-19
COVID-19 vaccine
Diagnosis
disease
dose
Evidence
first dose
geometric mean
geometric mean ratio
group
groups
had no
healthy control
healthy individuals
heterologous vaccine
homologous
IBD
Immunosuppressed
immunosuppressed patient
immunosuppressive
Immunosuppressive treatment
Infection
Inflammatory bowel disease
jak inhibitors
multicentre
multivariable
nine
no significant difference
Older
Older age
participant
Patient
patients treated
Pfizer
Primary outcome
receiving
Receptor binding domain
recipient
recruited
reduced
regimen
response
S1 RBD
SARS-COV-2 infection
SARS-CoV-2 spike
SARS-CoV-2 vaccination
significantly
significantly lower
Support
T-cell Response
T-cell responses
the healthy
therapy
Tofacitinib
Treatment
ulcerative colitis
Vaccine
vaccine dose
vaccine doses
vaccine-induced antibody response
VIP
were measured
[DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
[DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
Exploratory analysis of interleukin-38 in hospitalized COVID-19 patients
Article
[키워드] Adaptive immune response
Admission
age
Analysis
anti-inflammatory effect
anti-inflammatory properties
binding
Biomarker
cartilage
CD244
CHL1
circulating
Clinical data
Cohort
cohorts
Concentration
concentrations
coronavirus disease
correlated
correlation
COVID-19
COVID-19 patient
COVID-19 severity
disease
dismutase
dysregulated
enzyme-linked immunosorbent
exploratory
fatty
healthy control
healthy controls
healthy subjects
hospital
Hospitalization
hospitalized COVID-19 patient
hospitalized COVID-19 patients
IL-1
Immunoglobulin
in viral
increase in
infections
Inflammatory biomarker
intensive care
interleukin-38
investigated
men
moderate
Mortality
no difference
outcome
plasma
positive correlation
positively correlated
progression
Protein
proximity extension assay
recent
receptor
reduce
retrieved
retrospective cohort study
retrospective cohort study.
SARS-CoV-2
SERPINA12
severity
shown
subjects
thrombocyte
TNF
TNFRSF9
validation cohort
were measured
while
women
[DOI] 10.1002/iid3.712 PMC 바로가기
[DOI] 10.1002/iid3.712 PMC 바로가기
Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients
Article
Published on
Journal: Clinical gastroenterology and hepatology : the off
[Category] COVID19(2023년), SARS, 진단, 치료기술,
Journal: Clinical gastroenterology and hepatology : the off
[Category] COVID19(2023년), SARS, 진단, 치료기술,
[키워드] acute respiratory syndrome
anti-S
anti-SARS-CoV-2
antibody
Antibody Response
Antibody titer
cellular
Cellular immune response
coronavirus
COVID-19
defined
domain
dose
filtration
first vaccination
HCs
healthy control
humoral
immune response
Immunosuppression
increase
increase in
investigated
liver
liver transplant
liver transplant recipients
LTR
LTRs
Lymphocyte count
mRNA
mRNA-based
non-responders
Odds ratio
Patient
Prospective Study
RBD
recipient
responders
response
risk factor
SARS-CoV-2
SARS-CoV-2 vaccination
second vaccination
Seroconversion
seronegative
seropositive
spike-specific T-cell response
T cells
the median
Third and Fourth SARS-CoV-2 Vaccination.
Transplant
vaccination
Vaccinations
[DOI] 10.1016/j.cgh.2022.06.028 PMC 바로가기
[DOI] 10.1016/j.cgh.2022.06.028 PMC 바로가기
Immunogenicity and safety of two doses of SARS-CoV-2 mRNA vaccine in kidney transplant recipients with low-dose rituximab
Article
Published on
Journal: International journal of urology : official journa
[Category] COVID19(2023년), SARS, 진단,
Journal: International journal of urology : official journa
[Category] COVID19(2023년), SARS, 진단,
[키워드] acute respiratory syndrome
affected
antibody
antigen-specific T cell
baseline
cellular response
Control
controls
coronavirus
coronavirus disease
COVID-19
demonstrated
Deterioration
dose
enrolled
enzyme-linked immunospot
enzyme-linked immunospot assay
evaluated
healthcare worker
healthy control
humoral
immunogenicity
kidney
Kidney function
kidney transplant recipient
kidney transplant recipients
Kidney transplantation
lack
low-dose
mRNA
mRNA vaccine
multivariate regression analysis
not affect
not significantly different
profiles
rituximab.
SARS-CoV-2
Seroconversion
seroconversion rate
Spike protein
systemic adverse event
the vaccine
treatment history
vaccination
Vaccine
[DOI] 10.1111/iju.14978 PMC 바로가기
[DOI] 10.1111/iju.14978 PMC 바로가기
Identification of TCR repertoires in asymptomatic COVID-19 patients by single-cell T-cell receptor sequencing
Research article
[키워드] analyzed
Asymptomatic
Asymptomatic COVID-19
asymptomatic infection
cell-mediated immune response
Combination
COVID-19
COVID-19 patient
dominant
effective
FIVE
healthy control
help
identification
identify
Immunity
Immunopathogenesis
Immunotherapy
J gene
Patient
PBMC
performed
SARS-CoV-2
SARS-COV-2 infection
scTCR-seq
Sequencing
single-cell
skewed
study groups
subjects
symptomatic
T cell response
T-cell receptor
TCR
TCR repertoires
TCR sequencing
therapeutic strategy
viral infection
[DOI] 10.1016/j.bcmd.2022.102678 [Article Type] Research article
[DOI] 10.1016/j.bcmd.2022.102678 [Article Type] Research article
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
Article
Published on
Journal: Multiple sclerosis and related disorders
[Category] COVID19(2023년), SARS, 바이오마커, 진단, 치료기술,
Journal: Multiple sclerosis and related disorders
[Category] COVID19(2023년), SARS, 바이오마커, 진단, 치료기술,
[키워드] administration
age
anti-CD20
anti-CD20 therapy
Anti-SARS-CoV-2 S
antibody
Antibody Response
Antibody titer
appear
B-cell
CD20
cell count
Clinical outcome
Cohort
collected
Comprehensive
COVID-19
COVID-19 infection
COVID-19 vaccination
death
demographic
demonstrated
diagnosed with COVID-19
died
disease
Disease modifying therapy
effective
enrolled
female
FIVE
Follow-up
healthy control
healthy controls
humoral
Humoral immunity
Humoral response
ICU care
Immune profile
immunoglobulins
incidence
increased risk
investigation
less
longitudinal
Lymphocyte count
Multiple
multiple sclerosis
outcome
Patient
preventing infection
profile
reduced
required
Responder
response to vaccination
Result
retrospective
SARS-CoV-2 spike
sclerosis
serum
severe disease
significantly lower
single-center study
therapy
Treatment
vaccinated against COVID-19
vaccination
Vaccine
[DOI] 10.1016/j.msard.2022.104079 [Article Type] Article
[DOI] 10.1016/j.msard.2022.104079 [Article Type] Article
DNA damage in peripheral blood lymphocytes of severely ill COVID-19 patients in relation to inflammatory markers and parameters of hemostasis
Article
[키워드] activated
Analysis
Antibiotics
Anticoagulant
antiviral therapy
applied
Bearing
biochemical
C-reactive protein (CRP
Chest
chest X-ray
Concentration
contribute
control subjects
Corticosteroid
COVID-19
COVID-19 patient
COVID-19 patients
demonstrated
DNA
DNA damage
female
Female patients
Genetic
Genome
genotoxic
healthy control
healthy controls
hematological parameters
Hemostasis
hemostasis abnormalities
hospitalized COVID-19 patient
IL-6
indicated
Inflammation
Inflammation.
Inflammatory marker
Laboratory
laboratory parameter
Laboratory parameters
leukocyte
lymphocyte
neutrophil
parameter
performed
peripheral blood lymphocyte
Platelet
positive
positive correlation
positively correlated
procalcitonin
reagent
shown
significantly
significantly higher
smoking
statistically
study population
subjects
therapy
variety
viral infections
was measured
X ray
[DOI] 10.1093/mutage/geac011 PMC 바로가기
[DOI] 10.1093/mutage/geac011 PMC 바로가기